Experience from the University Hospitals Leuven: Targeted RNA sequencing for the detection of actionable oncogenic driver mutations in NSCLC

November 2023 Clinical Practice Jolien Blokken

Over the last decade we have witnessed a dramatic evolution in the treatment paradigm for patients with advanced non-small cell lung cancer (NSCLC). In this, targeted therapy has become the standard of care for subgroups of patients harboring specific oncogenic driver alterations. To facilitate an accurate and timely detection of these targetable molecular alterations, hospitals have adopted different strategies to optimize the molecular testing for patients with NSCLC. In this article, Prof. Christophe Dooms (thoracic oncologist), Prof. Birgit Weynand (pathologist) and Prof. Isabelle Vanden Bempt (clinical biologist) discuss how they addressed the challenges posed by the evolving molecular testing needs in patients with NSCLC.

In this interview Prof. Dooms, Prof. Weynand and Prof. Vanden Bempt shared their insights on the following questions:

What is the current workflow for molecular testing in patients with NSCLC?
What is the turnaround time you are able to achieve with this RNA-based strategy?
How do you think the molecular testing landscape for NSCLC patients will evolve in the years to come?

Read the complete interview here

This material is meant only for individuals allowed by law to prescribe or deliver medicines.

RP: Eli Lilly Benelux – Markiesstraat 1/4B Rue du Marquis, 1000 Brussel/Bruxelles

To provide the best experiences, we and our partners use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us and our partners to process personal data such as browsing behavior or unique IDs on this site and show (non-) personalized ads. Not consenting or withdrawing consent, may adversely affect certain features and functions.

Click below to consent to the above or make granular choices. Your choices will be applied to this site only. You can change your settings at any time, including withdrawing your consent, by using the toggles on the Cookie Policy, or by clicking on the manage consent button at the bottom of the screen.

Functional Always active

The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.

Preferences

The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.

Statistics

The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.

Marketing

The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.

Statistics

Marketing

Features

Always active

Experience from the University Hospitals Leuven: Targeted RNA sequencing for the detection of actionable oncogenic driver mutations in NSCLC

Share this article